This is a routine filing with no material new information. Traders should monitor upcoming earnings or press releases for any operational or financial updates.
RDY drugs
RDY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jul 1 $13.99entry
- T+1 · 5mo ago +2.79%α +2.92% · $14.38
- T+5 · 4mo ago +4.57%α +4.31% · $14.63
- T+20 · 4mo ago −15.94%α −13.75% · $11.76
- T+60 · due 8w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's Laboratories filed a Form 6-K on July 1, 2026, to furnish an intimation (Exhibit 99.1) to the SEC. The filing is a routine foreign issuer report with no material financial disclosures, business updates, or operational changes. The attached document content is not available for review, so the analysis is based solely on the filing metadata.
Key Facts
- Form 6-K filed July 1, 2026, as a routine foreign private issuer report
- Exhibit 99.1 is an intimation dated July 1, 2026, content of this exhibit is unavailable
- No financial results, guidance, material agreements, or operational updates disclosed in the filing
- Company has 834,656,970 equity shares outstanding per recent 20-F filing (May 29, 2026)
- Analysis based on filing metadata only, document content was unavailable
Financial Impact
No financial figures disclosed in this filing
Risk Factors
- Lack of document content limits visibility into the substance of the intimation filed as Exhibit 99.1
- No forward-looking guidance or strategic commentary provided in the filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000475 |
| Document: 0001575872-26-000475-index.html | 0001575872-26-000475 |
| Document: 0001575872-26-000475.txt | 0001575872-26-000475 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers